Stem Cell Screening: Fetal Tissue, Embryonic Cells, Both, or Neither?

Abstract

Negative screening to exclude companies involved in stem cell research is frequently elected by faith-based groups of differing denominational and religious beliefs. However, what is excluded is viewed variously by different groups. As a result, an array of conflicting approaches are taken by institutions in identifying values-based exclusions on stem cells. To illustrate, some faith-based groups take a restrictive approach and exclude companies involved in both fetal tissue and embryonic stem cell research, as well as the manufacturers of equipment enabling the research. Others take a more limited approach and exclude only companies involved in one, or the other, source of stem cells. Still others see all stem cell research as a medical benefit to mankind, and take no steps whatsoever to impede its progress. Making matters more confusing, language found in many institutions’ Investment Policy Statement (IPS) pertaining to stem cells is inexact. Too often, the terms ‘fetal’ and ‘embryonic’ are used interchangeably. It is important to understand the differences in research being undertaken to clearly define the preferred exclusion. We provide definitional distinctions, together with typical faith-based applications, as a guide to stem cell screening.